Iltefat H Hamzavi
Overview
Explore the profile of Iltefat H Hamzavi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
1215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yousif J, Ceresnie M, Hamzavi I, Mohammad T
Arch Dermatol Res
. 2023 Dec;
316(1):10.
PMID: 38038734
Vitiligo manifests as depigmented macules and patches on the skin and can significantly impact a patient's quality of life. Despite the availability of several treatment modalities, rates of repigmentation can...
12.
Desai S, F Alexis A, Elbuluk N, Grimes P, Weiss J, Hamzavi I, et al.
J Am Acad Dermatol
. 2023 Sep;
90(2):269-279.
PMID: 37748556
Background: Melasma is a chronic hypermelanosis of the skin that affects approximately 1% of the global population, predominantly affects women, and is more prevalent in skin of color. Melasma is...
13.
van Geel N, Speeckaert R, Taieb A, Ezzedine K, Lim H, Pandya A, et al.
J Eur Acad Dermatol Venereol
. 2023 Sep;
37(11):2173-2184.
PMID: 37746876
Background: The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long-term approach....
14.
Seneschal J, Speeckaert R, Taieb A, Wolkerstorfer A, Passeron T, Pandya A, et al.
J Eur Acad Dermatol Venereol
. 2023 Sep;
37(11):2185-2195.
PMID: 37715487
Background: The treatment of vitiligo can be challenging. Up-to-date agreed consensus recommendations on the use of topical and systemic therapies to facilitate the clinical management of vitiligo are currently lacking....
15.
Bibeau K, Ezzedine K, Harris J, van Geel N, Grimes P, Parsad D, et al.
JAMA Dermatol
. 2023 Aug;
159(10):1124-1128.
PMID: 37647073
Importance: Patients with vitiligo often have impaired quality of life (QOL) and experience substantial psychosocial burden. Objective: To explore the global association of vitiligo with QOL and mental health from...
16.
van Geel N, Duponselle J, Delbaere L, Herbelet S, Eleftheriadou V, Ezzedine K, et al.
J Eur Acad Dermatol Venereol
. 2023 Aug;
37(11):2231-2242.
PMID: 37602494
Clinician-reported outcome measures (ClinROMs) are essential for assessment of vitiligo in clinical trials and daily practice. Several instruments have been developed and tested to measure, for example, vitiligo extent, repigmentation...
17.
Maghfour J, Shoukfeh R, Hamzavi I, Ezzedine K, Mohammad T
J Eur Acad Dermatol Venereol
. 2023 Aug;
37(11):2270-2272.
PMID: 37566732
No abstract available.
18.
Hamzavi I, Bibeau K, Grimes P, Harris J, van Geel N, Parsad D, et al.
Br J Dermatol
. 2023 Jul;
189(5):569-577.
PMID: 37493275
Background: Vitiligo is a chronic autoimmune disease affecting melanocytes, resulting in skin depigmentation. Patients with vitiligo often have reduced quality of life and comorbid autoimmune conditions and have reported a...
19.
Maghfour J, Dzuali F, Ezekwe N, Gordon J, Hamzavi I
Br J Dermatol
. 2023 Jul;
189(6):764-783.
PMID: 37467744
No abstract available.
20.
Maghfour J, Liu V, Parks-Miller A, Hamzavi I
JID Innov
. 2023 May;
3(3):100192.
PMID: 37252321
Exclusion criteria can limit the generalizability and translation of research findings into clinical practice. The objective of this study is to characterize the trends of exclusion criteria and explore the...